open access

Ahead of print
Clinical vignette
Submitted: 2022-03-06
Accepted: 2022-04-09
Published online: 2022-07-28
Get Citation

Ruxolitinib-associated squamous cell carcinoma

Miguel Alpalhão123, Luís Soares-Almeida123, Paulo Filipe123
DOI: 10.5603/AHP.a2022.0037
Affiliations
  1. Dermatology and Venereology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte EPE, Lisbon, Portugal
  2. Dermatology and Venereology Universitary Clinic, Faculty of Medicine, University of Lisbon, Lisbon, Portugal
  3. Dermatology Research Unit, iMM João Lobo Antunes, University of Lisbon, Lisbon, Portugal

open access

Ahead of print
CLINICAL VIGNETTE
Submitted: 2022-03-06
Accepted: 2022-04-09
Published online: 2022-07-28

Abstract

Not available

Abstract

Not available
Get Citation

Keywords

JAK inhibitors, non-melanoma skin cancer, ruxolitinib

About this article
Title

Ruxolitinib-associated squamous cell carcinoma

Journal

Acta Haematologica Polonica

Issue

Ahead of print

Article type

Clinical vignette

Published online

2022-07-28

Page views

11

Article views/downloads

16

DOI

10.5603/AHP.a2022.0037

Keywords

JAK inhibitors
non-melanoma skin cancer
ruxolitinib

Authors

Miguel Alpalhão
Luís Soares-Almeida
Paulo Filipe

References (10)
  1. de Oliveira AB, Alpalhão M, Filipe P, et al. The role of Janus kinase inhibitors in the treatment of alopecia areata: a systematic review. Dermatol Ther. 2019; 32(5): e13053.
  2. Peterson DM, Vesely MD. Successful treatment of alopecia totalis with ruxolitinib in a preadolescent patient. JAAD Case Rep. 2020; 6(4): 257–259.
  3. Harris JE, Rashighi M, Nguyen N, et al. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA). J Am Acad Dermatol. 2016; 74(2): 370–371.
  4. Kvist-Hansen A, Hansen PR, Skov L. Systemic treatment of psoriasis with JAK inhibitors: a review. Dermatol Ther (Heidelb). 2020; 10(1): 29–42.
  5. Rodrigues MA, Torres T. JAK/STAT inhibitors for the treatment of atopic dermatitis. J Dermatolog Treat. 2020; 31(1): 33–40.
  6. Harrison CN, Vannucchi AM, Kiladjian JJ, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016; 30(8): 1701–1707.
  7. Lin JQ, Li SQ, Li S, et al. A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis. J Am Acad Dermatol. 2022; 86(2): 339–344.
  8. Barbui T, Ghirardi A, Masciulli A, et al. Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. Leukemia. 2019; 33(8): 1996–2005.
  9. Polverelli N, Elli EM, Abruzzese E, et al. Second primary malignancy in myelofibrosis patients treated with ruxolitinib. Br J Haematol. 2021; 193(2): 356–368.
  10. Curtis JR, Lee EB, Kaplan IV, et al. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme. Ann Rheum Dis. 2016; 75(5): 831–841.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl